Rivastigmine |
|
|
Article: Rivastigmine
| Image:Rivastigmine.png | |
| Rivastigmine | |
| Systematic (IUPAC) name | |
| 2,6-dioxo-4-phenyl-piperidine-3-carbonitrile | |
| Identifiers | |
| CAS number | 123441-03-2 |
| ATC code | N06DA03 |
| PubChem | 77991 |
| DrugBank | APRD00321 |
| Chemical data | |
| Formula | C14H22N2O2 |
| Mol. weight | 250.337 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 96% |
| Protein binding | 40% |
| Metabolism | ? |
| Half life | 1.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Rivastigmine tartrate (Exelon) is a medication developed and marketed by Novartis for the treatment of Alzheimer's disease and Dementia with Lewy bodies. The drug inhibits cholinesterase and butyrylcholinesterase and is designed for symptomatic treatment of early- to middle-stage Alzheimer's.
See also
- "Acetylcholinesterase inhibitors" section of the "Alzheimer's disease" article
| Anticholinesterases (N06DA, N07AA) edit |
| Metrifonate - Physostigmine - Neostigmine - Pyridostigmine - Ambenonium - Demarcarium - Rivastigmine - Galantamine - Donepezil - Tacrine - Edrophonium |
Categories: Antidementia agents | Pharmacologic agents | Novartis | Pharmacology stubs

Not Signed In -


